Clinical Trials Logo

Clinical Trial Summary

Cerebral vasospasm is characterized by a vasoconstriction of cerebral arteries causing a reduction of cerebral blood flow (CBF) and leading to ischemia and infarction of the brain parenchyma. Cerebral vasospasm is a serious complication of aneurysmal subarachnoid hemorrhage (SAH) with high morbidity and overall mortality of 40-50%. Although the exact mechanisms of spinal cord stimulation (SCS) on the innervation of cerebral vessels are still unclear, several hypotheses have been formulated and studies in animals and human performed with very promising results. This is a proof of concept study to better understand the effect and mechanisms of cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH in human.


Clinical Trial Description

Cerebral vasospasm is characterized by a vasoconstriction of cerebral arteries causing a reduction of cerebral blood flow (CBF) and leading to ischemia and infarction of the brain parenchyma. Cerebral vasospasm is a serious complication of aneurysmal subarachnoid hemorrhage (SAH) with high morbidity and overall mortality of 40-50%. The exact pathophysiological mechanisms underlying cerebral vasospasm are still not known in detail. A wide range of different therapeutic options with various efficacies are available, triple-H therapy and endovascular treatment options like intra-arterial application of vasodilators e.g. Nimodipine or Papaverine or transluminal balloon angioplasty have been reported and are applied to prevent and treat cerebral vasospasm after SAH. Calcium channel blockers such as nimodipine or nicardipine improve outcome in patients after SAH and reduce the risk of secondary ischemia. The benefit of the different therapies is undoubted, but there is still potential for improvement concerning the rate of morbidity and mortality. Although the exact mechanisms of spinal cord stimulation (SCS) on the innervation of cerebral vessels are still unclear, several hypotheses have been formulated and studies in animals and human performed with very promising results. This is a proof of concept study to better understand the effect and mechanisms of cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH in human. Subjects are enrolled into the study, if radiographical vasospasms are detected in CTA, CTP, cerebral angiography or TCD. SCS leads are implanted within 12h after study enrolment following the investigator's standard practice. SCS will be continuously delivered until day 14 after SAH. Doppler ultrasound is performed before SCS lead implantation and repeated after implantation on a daily basis and appearance of a new neurological deficit device until 24h after stopping the stimulation. Efficacy of cervical SCS is further evaluated by CTA or angiography and CTA/P performed 48h and 96h after lead implantation, as well as on day 14 after SAH before stopping the stimulation. The SCS electrode(s) are explanted on day 15. Intracerebral pressure is monitored from day 7-15. Headache, measured as NRS 0-10 and the consumption of analgesics are monitored from day 7-15, at discharge, at 3 and 6 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05150002
Study type Interventional
Source Insel Gruppe AG, University Hospital Bern
Contact Janine A Schlaeppi, MD
Phone +41 31 6320014
Email Janine.Schlaeppi@insel.ch
Status Recruiting
Phase N/A
Start date June 30, 2023
Completion date September 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Recruiting NCT04189471 - Recovery After Cerebral Hemorrhage
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Completed NCT02872857 - Subarachnoid Hemorrhage Recovery And Galantamine Phase 1/Phase 2
Completed NCT03164434 - Influence of Drainage on EVD ICP-signal
Terminated NCT02216513 - Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Phase 0
Completed NCT02389634 - Identification of Novel Molecular Markers for Vasospasm
Not yet recruiting NCT00905931 - Lycopene Following Aneurysmal Subarachnoid Haemorrhage Phase 2
Completed NCT01077206 - High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage Phase 2/Phase 3
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Completed NCT01261091 - Early Tracheostomy in Ventilated Stroke Patients N/A
Completed NCT00507104 - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
Completed NCT00071565 - Familial Intracranial Aneurysm Study II N/A
Recruiting NCT05113381 - The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH N/A
Completed NCT04052646 - Prehospital Deaths From Spontaneous Subarachnoid Haemorrhages
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting NCT06033378 - Blood Pressure Treatment in ICU Patients With Subarachniodal Haemorrhage. N/A
Completed NCT04308577 - Diet Induced Ketosis for Brain Injury - A Feasibility Study N/A